Long-Term Cancer Survivors Identify Ongoing Challenges Related to Ostomy Self-Management
In this study, researchers identified 8 common themes related to challenges patients experience with ostomy self-management.
Bladder Cancer News
BLADDER CANCER ADVISOR
Bladder Cancer News
Preoperative Pyuria Predicts Bladder Recurrence After UTUC Surgery
In a small study of patients without a history of bladder cancer who undergo radical nephroureterectomy for upper tract urothelial carcinoma, preoperative pyuria was associated with a 1.7-fold increased risk of intravesical recurrence, a study found.
NAC Increases Pathologic Complete Response Rate in High-Risk MIBC
In a study of patients with high-risk muscle-invasive bladder cancer, patients who received cisplatin-based neoadjuvant chemotherapy had a 3.6 times higher rate of pathologic complete response compared with those who had upfront radical cystectomy.
Immunotherapy + Chemo May Improve Outcomes in Metastatic Urothelial Cancer
First-line treatment with both atezolizumab and platinum-based chemotherapy (PBC) is associated with prolonged progression-free survival vs PBC alone in patients with metastatic urothelial cancer, a study found.
Women Have Lower Relative Survival After Bladder Cancer Diagnosis
In a study, women with bladder cancer had approximately 1.5-fold higher mortality than men — but only in the short term.
Robotic Partial Cystectomy Does Not Hike Positive Surgical Margin Risk
Investigators report finding no significant difference in positive surgical margin rates among open, laparoscopic, and robotic-assisted approaches to partial cystectomy.
Delayed RC for Histologic Variant Urothelial Bladder Cancer Ups Death Risk
Each 1-month delay in radical cystectomy following diagnosis of variant histology urothelial carcinoma of the bladder was associated with a 36% increased risk of death, a study found.
Robotic, Open Cystectomy for Bladder Cancer Offer Comparable Outcomes
In a propensity score matched analysis, robotic-assisted and open radical cystectomy for urothelial bladder cancer did not differ significantly with respect to disease recurrence and cancer-specific mortality rates.
Combo Shows Promise as Alternative for Metastatic Urothelial Carcinoma
In a phase 2 trial, a regimen of gemcitabine plus eribulin compared favorably with other regimens for the first-line treatment of cisplatin-ineligible patients with metastatic urothelial carcinoma.
UTUC With Isolated Lymph Node Involvement Predicts Poor Survival
Patients who undergo surgical resection of nonmetastatic upper tract urothelial carcinoma with isolated lymph node involvement have a 5-year overall survival rate of only 24%, a study found.
Guideline-Based Hematuria Evaluation May Up Risk of Secondary Cancers
Uniform use of computed tomography for hematuria workups marginally increases detection of urinary tract cancers while raising the risk for secondary cancers from imaging-associated radiation, researchers concluded.
Erdafitinib Achieves 40% Response Rate in Advanced Urothelial Cancers
In a phase 2 trial, erdafitinib demonstrated measurable antitumor activity in 40% of patients with FGFR3-mutant advanced urothelial cancers, investigators reported.
Frailty Predicts Higher In-Hospital Mortality After Radical Cystectomy
Frail patients are more likely than non-frail patients to experience adverse perioperative outcomes after radical cystectomy, a study found.
Poor Diabetes Control Linked to Worse NMIBC Outcomes
Among patients with non-muscle-invasive bladder cancer, those with diabetes and HbA1c levels below 7% have shorter progression-free survival.
Earlier Pembrolizumab Use May Be Beneficial in mUC
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
Adverse Events Associated With Outcomes in PD-1/PD-L1–Treated Urothelial Carcinoma
An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.
Enfortumab Vedotin Yields High Response Rate in Advanced Urothelial Cancer
The investigators said the data justify and support the submission of enfortumab vedotin for consideration under FDA’s accelerated approval pathway.
Inactivating Mutations in Genes Encoding for Components of the mSWI/SNF Complex May Be Associated With Improved OS in Immunotherapy-Treated Patients
The identification of biomarkers of response and resistance to immune checkpoint inhibitors remains an active area of research.
No Surgery in Nearly 11% of Localized UTUC Cases
In a study, median survival time was significantly shorter among patients managed nonsurgically rather than surgically for localized upper tract urothelial carcinoma.
UTUC Recurrence Risk Lowered With Adjuvant Chemotherapy
Adjuvant chemotherapy given to patients following underwent radical surgery for locally advanced upper tract urothelial carcinoma was associated with a significantly decreased risk of tumor recurrence.
Want to read more?
Please login or register first to view this content.
